Pacific Century Group’s insurance technology business, Bolttech, has extended a recent $180 million Series A round to $210 million in total.
500 Startups has closed its largest-ever global fund at $140 million, while simultaneously rebranding as 500 Global and expanding its strategy to include later-stage deals.
Pressure is mounting on Chinese companies listed in New York, from domestic and US regulators. Is another wave of PE-backed take-privates imminent?
A group of Chinese investors including Sky9 Capital, Ince Capital, and Draper Dragon have joined a $10 million round for non-fungible token (NFT) marketplace Cybertino Lab.
Japan’s Shiseido has extended a program of non-core divestments with the sale of three of its US makeup brands to Advent International for $700 million.
Blackbird Ventures has led a $25 million Series B funding round for Forage, an Australia-founded but now US-based provider of virtual training courses aimed at students.
PatPat, a Chinese-founded children’s wear brand, has raised $160 million from Softbank Vision Fund in a Series D round extension.
Suyi Kim, head of Asia Pacific at Canada Pension Plan Investment Board (CPPIB), has been named senior managing director and global head of private equity.
PatPat, a Chinese-founded children’s wear brand that claims to be the world’s largest direct-to-consumer (DTC) player in its segment, has raised $510 million across two rounds of funding.
Sherpa Healthcare Partners has led a $30 million Series A for Paq Therapeutics, a Chinese-founded biotech company specializing in treatments based on molecules that enhance the degradation of disease-causing entities.
Early-stage investor SOSV – known for accelerator programs such as China-based HAX and Chinaccelerator – has raised $100 million for its first growth fund designed to invest in Series B rounds and beyond.
Pacific Equity Partners (PEP) is poised to exit American Stock Transfer & Trust (AST), its longest-held portfolio company, following an agreement to sell the business to US-based Siris Capital.
Bolttech, a one-year-old company controlled by Pacific Century Group, has raised $180 million at a valuation of $1 billion. It is being called the largest-ever Series A round in insurance technology.
Panviva, an Australian cloud-based enterprise software provider backed by a number of venture capital investors, has been acquired by US counterpart Upland Software for about $23.3 million.
NewQuest Capital Partners is exiting Integreon, a business process outsourcing (BPO) provider with a significant Asia footprint to US private equity firm EagleTree Capital.
Sendle, an Australia-based package delivery provider for small businesses that claims to be 100% carbon neutral, has raised a $35 million Series C round led by local investor AP Ventures.
KPCB growth-stage spinout Bond has led a $200 million Series B round for BrowserStack, a software testing platform established by two Indian entrepreneurs.
Family offices have helped iGlobe Partners renew a lean and restrained deep tech VC mandate. A global investee network is hoped to facilitate overseas investments amid travel stoppages
ChrysCapital has exited Silicon Valley-based Infogain – an IT services provider that helped solidify the US-India cross-border opportunity set – to Apax Partners.
TPG Capital has led an $80 million Series D extension for Zenoti, an India-founded and US-headquartered software provider for the spa and wellness industry.
The US International Development Finance Corporation (DFC) – formerly the Overseas Private Investment Corporation (OPIC) – has made commitments to funds being raised by Southeast Asia-focused Openspace Ventures and India’s Chiratae Ventures.
The Blackstone Group has agreed to acquire International Data Group (IDG) from China Oceanwide Holdings for an enterprise valuation of $1.3 billion.
TA Associates, a global growth-oriented investor with a presence in Asia, has closed its 14th flagship fund at the hard cap of $12.5 billion.
With big pharma scaling back early-stage discovery, CBC Group is keen to incubate biotech start-ups developing drugs from scratch. NiKang Therapeutics is the first to secure wider investor attention